Navigation Links
Connecticut's Universities Team Up to Host 2009 Stem Cell Symposium
Date:10/6/2008

Scientific presentations and workshops to highlight two day event

NEW HAVEN, Conn., Oct. 6 /PRNewswire/ -- The StemCONN 09 stem cell symposium will bring the stem cell research community to New Haven, Conn., March 23 - 24, 2009.

Building on the successful StemCONN 07, which brought 700 scientists, business leaders and students to Hartford last year, StemCONN 09 will showcase the latest advances in stem cell research and their potential medical applications. Included in the two day event are scientific presentations by leading authorities, as well as sessions on the translation of scientific research to the clinic, emerging technologies and bioethics.

StemCONN 09 will include:

-- A scientific session featuring presentations by Kevin Eggan Ph.D. and

Konrad Hochedlinger Ph.D., both of Harvard University; Craig T. Jordan

Ph.D., University of Rochester; Thomas A. Rando M.D., Ph.D., of Stanford

University; Celeste Simon Ph.D., University of Pennsylvania, and Sally

Temple Ph.D., Albany Medical Center.

-- A session on bioethics organized by Lori Gruen Ph.D., of Wesleyan

University in collaboration with Anne Hiskes Ph.D., of the University of

Connecticut.

-- A session on "Translation to Clinic" that will look at the

opportunities and barriers to converting stem cell research to therapies

as well as promising options for using stem cells for drug discovery.

With its 10-year, $100 million stem cell research grant program, Connecticut has emerged as an innovative leader in the field of stem cell research. The state is home to leading academic institutions specializing in this area, including Yale University, the University of Connecticut and Wesleyan University, providing a culture where national and international stem cell research partnerships develop, thrive and grow.

Organizing StemCONN 09 are Yale University, Wesleyan Univers
'/>"/>

SOURCE CURE (Connecticut United for Research Excellence)
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Aerospace engineer earns Oak Ridge Associated Universities Ralph Powe Junior Faculty Award
2. Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities.
3. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
4. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
5. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
6. Aureus Pharma Announces Date of 2008 Annual User Symposium
7. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
8. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
9. International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece
10. CryoLife Conducts Surgeons Cardiac Allograft Symposium
11. DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... MANOR, N.Y., Dec. 15 On January ... International Society for Medical Publication Professionals (ISMPP) will ... in London, UK. More than 100 attendees are ... forum for publication professionals, editors, publishers, medical writers ... of medical publications and the impact of guidelines ...
(Date:12/14/2009)... Colo. and THOUSAND OAKS, Calif., Dec. 14 /PRNewswire-FirstCall/ ... and Amgen Inc.(Nasdaq: AMGN ) today announced ... exclusive worldwide rights to Array,s small-molecule glucokinase activator ... Phase 1 clinical trial in patients with Type ... of the agreement, Array will receive an upfront ...
(Date:12/14/2009)... ROCKAWAY, N.J., Dec. 14 The third ... Approach , published by the ... FDA-approved treatment for anthracycline extravasation.(1) Anthracyclines are ... idarubicin and epirubicin that have been used in ... the early 1970s.(2) ,, According to ...
(Date:12/14/2009)... Decision Resources, one of the world,s leading research ... finds that, owing to the launches of several ... increase more than sevenfold from $790 million in ... United States, France, Germany, Italy, Spain, the United ... entitled Atrial Fibrillation finds that a ...
Breaking Biology Technology:Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
... vaccine progresses with study designed to select dose for ... Inc. (Nasdaq: NVAX ) announced today vaccination ... its virus-like particle (VLP) seasonal influenza vaccine. Building on ... placebo controlled clinical trial has been designed to evaluate ...
... Novagali Pharma, a French,pharmaceutical ophthalmic company, announces ... (IND) to conduct a Phase III clinical,trial ... glaucoma has been,granted by the U.S. Food ... ocular proprietary BAK-free formulation of latanoprost which,furthermore ...
... Calif., May 5 Poniard Pharmaceuticals, Inc. (Nasdaq: ... Monitoring Committee (DMC), after review of available information regarding ... that the SPEAR (Study of Picoplatin Efficacy After Relapse) ... evaluating the efficacy and safety of picoplatin in patients ...
Other Biology Technology:Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 4Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer 2Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer 3Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer 4Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer 5
(Date:12/16/2009)... more than 4 billion years before humans showed up, ... more. That suggests they may have something to teach ... expert Prof. Eshel Ben-Jacob of the Raymond and Beverly ... study of bacteria, presents compelling evidence to suggest there ... automatically opt for the swine flu H1N1 shot. , ...
(Date:12/16/2009)... 1 GestureTek Inc. today announced ... - a turnkey, portable, plug and play ... entertainment and touring promotions. GestureTek is the ... in camera-enabled gesture recognition technology for interactive ... for quality, the CUBE has TUV, CE, ...
(Date:12/16/2009)... TORONTO, Dec. 7 IgeaCare Solutions Inc. ... assets of the healthcare communications company previously operating ... Solutions will now move forward under new leadership ... Mr. Michael Rochon to the position of Chief ... will focus on providing a superior servicing and ...
Breaking Biology News(10 mins):Bacteria wouldn't opt for a swine flu shot 2Bacteria wouldn't opt for a swine flu shot 3GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 50686 1Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 50686 2Kids With Type 1 Diabetes Often Overweight 50682 1Kids With Type 1 Diabetes Often Overweight 50682 2 28RED 29ZONES Launch at First U2 360 Degrees Concert in Barcelona 50678 1 28RED 29ZONES Launch at First U2 360 Degrees Concert in Barcelona 50678 2 28RED 29ZONES Launch at First U2 360 Degrees Concert in Barcelona 50678 3
... , Fast identification of animal meat for human consumption ... for consumers and producers. Consumption of Iberian pig meat is ... maximum gastronomic quality. In the last years, a booming economic ... Spanish borders: Iberian ham, dried meat, cold meats and cold ...
... London, New Delhi, and Singapore (April 28, 2008) ... more and more common. Weight and eating disorders have ... for more information about how to deal with pediatric ... fifth largest publisher of journals, is launching its newest ...
... inextricably linked. However, new research published in BioMed Centrals ... this may not always hold true, although it may ... , The land and the oceans contain significantly more ... the atmosphere. The amount of CO2 emissions absorbed by ...
Other Biology News:New computer applications allow to classify Iberian pig meat automatically 2